Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Br J Psychiatry. 2004 Aug;185:147-51.

Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele.

Author information

  • 1Alcohol Research Center, Neuropsychiatric Institute, University of California, Los Angeles, CA 90024-1759, USA. epnoble@ucla.edu

Abstract

BACKGROUND:

Hyperprolactinaemia induced by D(2) dopamine receptor antagonist antipsychotic medication can result in significant health problems.

AIMS:

To examine the role of DRD2 polymorphism on prolactin levels in patients treated with antipsychotic medication.

METHOD:

Antipsychotic drugs with different degrees of D(2) receptor binding were given to 144 patients with schizophrenia. Serum prolactin levels were obtained and Taq1A DRD2 alleles were determined.

RESULTS:

Prolactin levels increased across medication groups reflecting increasingly tight D(2) receptor binding (clozapine, olanzapine, typical antipsychotics and risperidone). In the combined medication group, patients with the DRD2(*)A1allele had 40% higher prolactin levels than patients without this allele. In patients treated with clozapine (the loosest D(2) receptor binding agent), patients with the DRD2(*)A1allele had prolactin levels twice those of patients without this allele.

CONCLUSIONS:

Patients with the DRD2A1 allele receiving antipsychotic medications had higher prolactin levels and were overrepresented among those with hyperprolactinaemia, suggesting greater functional D(2) receptor binding in this group.

PMID:
15286066
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk